GSK's targeted cancer therapy shows promise, hints at blockbuster potential

• Early trial data showed 62% of platinum-resistant ovarian cancer patients and 67% of endometrial cancer patients achieved at least 30% tumor shrinkage
• Mo-rez targets the B7H4 protein found on gynecological cancer cells while largely avoiding healthy tissue; the antibody-drug conjugate market is projected to reach $31 billion by 2030
• GSK licensed the drug from China's Hansoh Pharma in 2023 and is moving forward with two ongoing late-stage trials plus three additional studies planned for coming months

GSK's Mo-rez Cancer Drug Shows Blockbuster Potential in Early Trials

British pharmaceutical giant GSK has released promising early-stage data for its experimental cancer drug Mo-rez, with the company's head of oncology research, Hesham Abdullah, projecting blockbuster potential for the treatment.

Key Trial Results:

The early data, presented at a medical conference in Puerto Rico, showed significant tumor reduction in patients with advanced, difficult-to-treat cancers:

• 62% of platinum-resistant ovarian cancer patients achieved at least 30% tumor shrinkage
• 67% of endometrial cancer patients met the same threshold

Drug Mechanism and Market:

Mo-rez is an antibody-drug conjugate (ADC) targeting the B7H4 protein found on gynecological cancer cells while largely sparing healthy tissue. The ADC treatment market is projected to reach $31 billion by 2030. GSK licensed the drug from China's Hansoh Pharma in 2023.

Development Timeline:

GSK is currently testing Mo-rez in two late-stage trials for ovarian and endometrial cancers and plans to initiate three additional studies in the coming months, bringing the total to five late-stage trials.

Strategic Context:

The positive data strengthens GSK's growing oncology business under new CEO Luke Miels, who assumed the role in January and has committed to accelerating drug development. Abdullah confirmed this faster pace is already reflected in product development programs.

Market Outlook:

While analysts have not yet projected future sales figures given the early-stage nature of the data, GSK leadership's confidence in blockbuster potential signals significant revenue expectations for this priority asset.